Overview

Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin

Status:
Unknown status

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the treatment effect at week 26 between the two groups, sulfonylurea (SU, glimepiride) administration and thiazolidinedione (TZD, Pioglitazone) administration, as the third-order drug among patients whose treatment is not sufficient after the combined administration of Metformin and Alogliptin.

Phase:

Phase 4

Details

Lead Sponsor:

Pusan National University Hospital

Treatments:

Alogliptin
Glimepiride
Metformin
Pioglitazone